News

Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors

.
  • Tubulis continues expansion of its clinical pipeline with a second ADC drug candidate entering the clinic
  • TUB-030 is a next-generation ADC targeting 5T4 with an exatecan payload, developed based on Tubulis’ proprietary P5 conjugation technology, which has demonstrated effective and durable responses in a range of preclinical solid tumor models
  • The 5-STAR 1-01 clinical trial will enroll up to 130 patients with advanced solid tumors in the US and Canada with the dose optimization cohort focusing on selected major cancer indications

MUNICH, GERMANY, January 30, 2025 – Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa trial (NCT06657222). The study is evaluating TUB-030, Tubulis’ next-generation antibody-drug conjugate (ADC), in patients with advanced solid tumors. The ADC targets 5T4, an oncofetal antigen expressed in a broad range of solid tumors.

https://tubulis.com/news/tubulis-announces-first-patient-dosed-in-phase-i-iia-trial-evaluating-adc-tub-030-in-advanced-solid-tumors/